Nordson Corporation Reports Third Quarter Fiscal 2024 Results and Updates Annual Guidance

Third Quarter Highlights:

- Sales were \$662 million, an increase of 2% year-over-year and in-line with mid-point of guidance
- Earnings per diluted share were \$2.04
- Adjusted earnings per diluted share were \$2.41, \$0.08 above the mid-point of guidance

Updated Full-Year Guidance:

- Increasing full fiscal year 2024 revenue guidance to reflect the addition of Atrion acquisition
- Maintaining full fiscal year 2024 adjusted earnings per diluted share guidance, inclusive of the slightly dilutive fourth quarter Atrion acquisition impact

WESTLAKE, Ohio--(BUSINESS WIRE)--August 21, 2024--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal third quarter ended July 31, 2024. Sales were \$662 million, compared to the prior year's third quarter sales of \$649 million. The third quarter 2024 sales included a favorable acquisition impact of 4%, partially offset by an organic sales decrease of 1% and unfavorable currency translation of 1%. The organic sales decrease was driven by lower demand in electronics and medical product lines, partially offset by growth in packaging, nonwovens, and optical sensors product lines.

Net income was \$117 million, or \$2.04 of earnings per diluted share, compared to prior year's third quarter net income of \$128 million, or \$2.22 of earnings per diluted share. Adjusted net income was \$138 million, a decrease from the prior year adjusted net income of \$147 million. Third quarter 2024 adjusted earnings per diluted share were \$2.41, a 6% decrease from the prior year adjusted earnings per diluted share of \$2.55. The decrease reflects increased interest expense from prior year acquisitions and slightly lower overall operating margins.

EBITDA in the third quarter was \$208 million, or 31% of sales, compared to prior year EBITDA of \$208 million, or 32% of sales. EBITDA was flat as improved gross margins were offset by higher selling and administrative expenses, including the first-year effect of the ARAG acquisition.

Commenting on the Company's fiscal 2024 third quarter results, Nordson President and Chief Executive Officer Sundaram Nagarajan said, "We delivered third quarter revenue in line with our expectations, driven by strong organic growth in our industrial product lines. Our Advanced Technology Solutions segment sequentially grew compared to second quarter, as order entry steadily improves in electronics end markets. Across the company, the teams executed another solid operating performance delivering strong gross margins and 31% EBITDA margin. Overall, I am pleased with our focus on the customer while managing profitability well against headwinds in select businesses."

Third Quarter Segment Results

Industrial Precision Solutions sales of \$371 million increased 10% from the prior year, inclusive of a favorable acquisition impact of 7%, an organic sales increase of 4% and unfavorable currency translation of 1%. The organic sales increase was driven primarily by packaging and nonwovens product lines. Operating profit was \$118 million, an increase of \$3 million from the prior year. EBITDA in the quarter was \$135 million, or 36% of sales, a 10% increase from the prior year third quarter EBITDA of \$122 million, or 36% of sales. The year-over-year increase was driven by the ARAG acquisition, and higher organic sales and gross profit.

Medical and Fluid Solutions sales of \$167 million decreased 2% compared to the prior year third quarter. The decrease was driven by lower demand in interventional solutions and fluid components product lines. Operating profit was \$48 million, a decrease of

\$6 million from the prior year. EBITDA in the quarter was \$62 million, or 37% of sales, down versus the prior year third quarter EBITDA of \$68 million, or 40% of sales.

Advanced Technology Solutions sales of \$124 million decreased 11% compared to the prior year third quarter, driven by lower organic sales and unfavorable currency translation of 1%. While sequentially higher, the organic sales decrease compared to prior year was driven by softness in electronics processing and x-ray and test product lines, offset by growth in optical sensors product lines. Operating profit was \$23 million, a decrease of \$4 million from the prior year. EBITDA in the quarter was \$26 million, or 21% of sales, a decrease from the prior year third quarter EBITDA of \$33 million, or 24% of sales.

Outlook

The Company is entering the fourth quarter of fiscal 2024 with approximately \$650 million in backlog, which continues to normalize and remain concentrated in systems businesses. Based on current visibility and order entry trends, the Company is increasing its full-year revenue guidance range to \$2,665 million - \$2,705 million, inclusive of revenue from the Atrion acquisition in the fiscal fourth quarter. The Company is tightening full-year adjusted earnings per diluted share to the range of \$9.45 - \$9.65, unchanged at the midpoint, though now inclusive of the slightly dilutive Atrion impact in the fiscal fourth quarter.

Reflecting on the outlook, Nagarajan continued, "Throughout 2024, we have remained focused on delivering high quality operating performance in a dynamic environment. The diversification of our product portfolio, geographic exposure, mix of recurring revenue, in addition to the NBS Next growth framework and the contributions of our recent acquisitions, are positioning us well to end the year in line with record fiscal 2023 revenue. I remain pleased with our ability to manage profitability during this period, while remaining invested in the long-term objectives of the business."

Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on Thursday, August 22, 2024 at 8:30 a.m. eastern time, which can be accessed at https://investors.nordson.com. Information about Nordson's investor relations and shareholder services is available from Lara Mahoney, vice president, investor relations and corporate communications at (440) 204-9985 or lara.mahoney@nordson.com.

The Company's definition of adjusted earnings excludes acquisition related amortization for both current and historical periods. It is not possible for the Company to identify the amount or significance of future adjustments associated with acquisition and integration costs, restructuring costs, acquisition-related amortization, certain non-operating or income tax items, or other non-routine costs that the Company adjusts in the presentation of adjusted earnings guidance. These items are dependent on future events that are not reasonably estimable at this time. Accordingly, the Company is unable to reconcile without unreasonable effort the forecasted range of adjusted earnings guidance to a comparable GAAP range.

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," "target," or the negative of these terms or comparable terminology. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company's ability to successfully integrate acquisitions; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine, acts of terror, natural disasters and pandemics, including the recent coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company's most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, linkedin/Nordson, or www.facebook.com/nordson.

CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(Dollars in thousands except for per-share amounts)

	Three Months Ended					Nine Months Ended				
	Ju	ly 31, 2024	Jı	uly 31, 2023	J	uly 31, 2024	Jı	uly 31, 2023		
Sales	\$	661,604	\$	648,677	\$	1,945,439	\$	1,909,319		
Cost of sales		292,603		288,357		862,134		868,007		
Gross profit		369,001		360,320		1,083,305		1,041,312		
Gross margin %		55.8 %		55.5 %		55.7 %		54.5 %		
Selling & administrative expenses		201,943		189,324		588,196		553,590		
Operating profit		167,058		170,996		495,109		487,722		
Interest expense - net		(17,776)		(11,486)		(56,729)		(30,904)		
Other income (expense) - net		152		2,542		(971)		(2,059)		
Income before income taxes		149,434		162,052		437,409		454,759		
Income taxes		32,107		34,161		92,293		95,044		
				_		_				
Net income	\$	117,327	\$	127,891	\$	345,116	\$	359,715		
Weighted-average common shares outstanding:										
Basic		57,229		56,989		57,171		57,114		
Diluted		57,624		57,530		57,620		57,657		
Earnings per share:										
Basic earnings	\$	2.05	\$	2.24	\$	6.04	\$	6.30		
Diluted earnings	\$	2.04	\$	2.22	\$	5.99	\$	6.24		

CONSOLIDATED BALANCE SHEETS (Unaudited)

(Dollars in thousands)

	Ju	ly 31, 2024	Octo	ber 31, 2023
Cash and cash equivalents	\$	165,324	\$	115,679
Receivables - net		538,541		590,886
Inventories - net		438,167		454,775
Other current assets		82,106		67,970
Total current assets		1,224,138		1,229,310
Property, plant and equipment - net		401,415		392,846
Goodwill		2,785,773		2,784,201
Other assets		793,044		845,413
	\$	5,204,370	\$	5,251,770
Notes payable and debt due within one year	\$	96,288	\$	115,662
Accounts payable and accrued liabilities		421,979		466,427
Total current liabilities		518,267		582,089
Long-term debt		1,398,155		1,621,394
Other liabilities		434,191		450,227
Total shareholders' equity		2,853,757		2,598,060
	\$	5,204,370	\$	5,251,770

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (Dollars in thousands)

		s Ended	
	July	y 31, 2024	July 31, 2023
Cash flows from operating activities:			
Net income	\$	345,116 \$	359,715
Depreciation and amortization		99,646	80,637
Other non-cash items		15,435	18,523
Changes in operating assets and liabilities and other		(385)	19,197
Net cash provided by operating activities		459,812	478,072
Cash flows from investing activities:			
Additions to property, plant and equipment		(43,786)	(24,244)
Acquisition of businesses, net of cash acquired		_	(377,843)
Other - net		8,896	91
Net cash used in investing activities		(34,890)	(401,996)
Cash flows from financing activities:			
Issuance (repayment) of long-term debt		(244,355)	73,956
Repayment of finance lease obligations		(4,505)	(4,769)
Dividends paid		(116,789)	(111,547)
Issuance of common shares		29,142	18,449
Purchase of treasury shares		(34,105)	(78,163)
Net cash provided used in financing activities		(370,612)	(102,074)
Effect of exchange rate change on cash:		(4,665)	5,679
Net change in cash and cash equivalents		49,645	(20,319)
Cash and cash equivalents:			
Beginning of period		115,679	163,457
End of period	\$	165,324 \$	5 143,138

SALES BY GEOGRAPHIC SEGMENT (Unaudited) (Dollars in thousands)

		Three Mor	nths	Ended		Sales Variance				
	Ju	ly 31, 2024	Ju	ıly 31, 2023	Organic	Acquisitions	Currency	Total		
SALES BY SEGMENT										
Industrial Precision Solutions	\$	370,561	\$	338,257	3.6 %	7.4 %	(1.4)%	9.6 %		
Medical and Fluid Solutions		166,737		170,871	(2.0)%	— %	(0.4)%	(2.4)%		
Advanced Technology Solutions		124,306		139,549	(10.2)%	<u> </u>	(0.7)%	(10.9)%		
Total sales	\$	661,604	\$	648,677	(0.9)%	3.8 %	(0.9)%	2.0 %		
SALES BY GEOGRAPHIC REGION										
Americas	\$	287,016	\$	290,515	(3.4)%	2.4 %	(0.2)%	(1.2)%		
Europe		179,370		167,536	(2.0)%	9.8 %	(0.7)%	7.1 %		
Asia Pacific		195,218	in i	190,626	4.1 %	0.8 %	(2.5)%	2.4 %		
Total sales	\$	661,604	\$	648,677	(0.9)%	3.8 %	(0.9)%	2.0 %		
		Nine Mor	nths	Ended		Sales Va	ariance			
	Ju	Nine Mor ly 31, 2024		Ended aly 31, 2023	Organic	Sales Va Acquisitions	ariance Currency	Total		
SALES BY SEGMENT	Ju				Organic			Total		
SALES BY SEGMENT Industrial Precision Solutions	Ju \$				Organic 2.5 %			Total		
		ly 31, 2024	Ju	ıly 31, 2023		Acquisitions	Currency			
Industrial Precision Solutions		ly 31, 2024 1,092,099	Ju	985,610	2.5 %	Acquisitions 8.8 %	Currency (0.5)%	10.8 %		
Industrial Precision Solutions Medical and Fluid Solutions		1,092,099 495,229	Ju	985,610 491,683	2.5 % 0.9 %	Acquisitions 8.8 % — %	(0.5)% (0.2)%	10.8 % 0.7 %		
Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions	\$	1,092,099 495,229 358,111	\$	985,610 491,683 432,026	2.5 % 0.9 % (16.6)%	8.8 % - % - %	(0.5)% (0.2)% (0.5)%	10.8 % 0.7 % (17.1)%		
Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions Total sales SALES BY GEOGRAPHIC	\$	1,092,099 495,229 358,111	\$	985,610 491,683 432,026	2.5 % 0.9 % (16.6)%	8.8 % - % - %	(0.5)% (0.2)% (0.5)%	10.8 % 0.7 % (17.1)%		
Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions Total sales SALES BY GEOGRAPHIC REGION	\$	1,092,099 495,229 358,111 1,945,439	\$ \$	985,610 491,683 432,026 1,909,319	2.5 % 0.9 % (16.6)% (2.2)%	8.8 % % % 4.5 %	(0.5)% (0.2)% (0.5)% (0.4)%	10.8 % 0.7 % (17.1)% 1.9 %		
Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions Total sales SALES BY GEOGRAPHIC REGION Americas	\$	1,092,099 495,229 358,111 1,945,439	\$	985,610 491,683 432,026 1,909,319	2.5 % 0.9 % (16.6)% (2.2)%	8.8 % — % — % 4.5 %	(0.5)% (0.2)% (0.5)% (0.4)%	10.8 % 0.7 % (17.1)% 1.9 %		
Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions Total sales SALES BY GEOGRAPHIC REGION Americas Europe	\$	1,092,099 495,229 358,111 1,945,439 855,456 540,750	\$ \$	985,610 491,683 432,026 1,909,319 834,125 498,379	2.5 % 0.9 % (16.6)% (2.2)% (0.3)% (4.5)%	8.8 % - % - % 4.5 % 2.7 % 12.2 %	(0.5)% (0.2)% (0.5)% (0.4)%	10.8 % 0.7 % (17.1)% 1.9 % 2.6 % 8.5 %		
Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions Total sales SALES BY GEOGRAPHIC REGION Americas	\$	1,092,099 495,229 358,111 1,945,439	\$ \$	985,610 491,683 432,026 1,909,319	2.5 % 0.9 % (16.6)% (2.2)%	8.8 % — % — % 4.5 %	(0.5)% (0.2)% (0.5)% (0.4)%	10.8 % 0.7 % (17.1)% 1.9 %		

RECONCILIATION OF NON-GAAP MEASURES - NET INCOME TO EBITDA (Unaudited) (Dollars in thousands)

		Three Mor	nths	Ended	Nine Months Ended			
	Jul	y 31, 2024	Jı	uly 31, 2023	July	y 31, 2024	Jul	y 31, 2023
Net income	\$	117,327	\$	127,891	\$	345,116	\$	359,715
Income taxes		32,107		34,161		92,293		95,044
Interest expense - net		17,776		11,486		56,729		30,904
Other expense - net		(152)		(2,542)		971		2,059
Depreciation and amortization		33,382		27,102		99,646		80,637
Inventory step-up amortization (1)		_				2,944		4,306
Severance and other		2,536		2,049		4,615		5,487
Acquisition-related costs (1)		5,160		7,732		5,757		13,721
EBITDA (non-GAAP) (2)	\$	208,136	\$	207,879	\$	608,071	\$	591,873

⁽¹⁾ Represents fees, severance and non-cash inventory charges associated with acquisitions.

⁽²⁾ EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.

RECONCILIATION OF NON-GAAP MEASURES - EBITDA (Unaudited) (Dollars in thousands)

	Thre	ee Months Ended	Nine Mo	nths Ended
	July 31, 20	July 31, 20	July 31, 2024	July 31, 2023
SALES BY SEGMENT			•	
Industrial Precision Solutions	\$ 370,561	\$ 338,257	\$1,092,099	\$ 985,610
Medical and Fluid Solutions	166,737	170,871	495,229	491,683
Advanced Technology Solutions	124,306	139,549	358,111	432,026
Total sales	\$ 661,604	\$ 648,677	\$1,945,439	\$1,909,319
OPERATING PROFIT				
Industrial Precision Solutions	\$ 118,110	\$ 115,346	\$ 344,305	\$ 329,439
Medical and Fluid Solutions	48,374	54,019	143,467	141,326
Advanced Technology Solutions	22,945	27,083	60,767	70,136
Corporate	(22,371)	(25,452)	(53,430)	(53,179)
Total operating profit	\$ 167,058	\$ 170,996	\$ 495,109	\$ 487,722
OPERATING PROFIT ADJUSTMEN	<u>TS</u> (1)			
Industrial Precision Solutions	\$ 2,536	\$ —	\$ 6,077	\$ —
Medical and Fluid Solutions	_	_	_	1,479
Advanced Technology Solutions	_	2,049	2,078	14,303
Corporate	5,160	7,732	5,161	7,732
Total adjustments	\$ 7,696	\$ 9,781	\$ 13,316	\$ 23,514
DEPRECIATION & AMORTIZATIO	N			
Industrial Precision Solutions	\$ 14,521	\$ 7,036	\$ 42,821	\$ 21,166
Medical and Fluid Solutions	13,553	14,133	40,822	41,441
Advanced Technology Solutions	3,368	3,834	10,093	11,656
Corporate	1,940	2,099	5,910	6,374
Total depreciation & amortization	\$ 33,382	\$ 27,102	\$ 99,646	\$ 80,637
EBITDA (NON-GAAP) (2)				
Industrial Precision Solutions	\$ 135,167	36% \$ 122,382	36% \$ 393,203 36%	\$ 350,605 36%
Medical and Fluid Solutions	61,927	37% 68,152	40% 184,289 37%	184,246 37%
Advanced Technology Solutions	26,313	21% 32,966	24% 72,938 20%	96,095 22%
Corporate	(15,271)	(15,621)	(42,359)	(39,073)
Total EBITDA	\$ 208,136	31% \$ 207,879	32% \$ 608,071 31%	\$ 591,873 31%

⁽¹⁾ Represents severance as well as fees and non-cash inventory charges associated with acquisitions.

⁽²⁾ EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.

RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED NET INCOME AND EARNINGS PER SHARE (Unaudited)

(Dollars in thousands)

		Three Months Ended				Nine Months Ended			
	Ju	July 31, 2024		July 31, 2023		July 31, 2024		ly 31, 2023	
GAAP AS REPORTED									
Operating profit	\$	167,058	\$	170,996	\$	495,109	\$	487,722	
Other / interest expense - net		(17,624)		(8,944)		(57,700)		(32,963)	
Net income		117,327		127,891		345,116		359,715	
Diluted earnings per share	\$	2.04	\$	2.22	\$	5.99	\$	6.24	
Shares outstanding - diluted		57,624		57,530		57,620		57,657	
OPERATING PROFIT ADJUSTMENTS									
Inventory step-up amortization	\$	_	\$	_	\$	2,944	\$	4,306	
Acquisition-related costs		5,160		7,732		5,757		13,721	
Severance and other		2,536		2,049		4,615		5,487	
ACQUISITION AMORTIZATION OF INTANGIBLES	\$	19,202	\$	13,922		57,412		41,839	
Total adjustments	\$	26,898	\$	23,703	\$	70,728	\$	65,353	
Adjustments net of tax	\$	21,134	\$	18,706	\$	55,804	\$	51,694	
EPS effect of adjustments and other discrete tax items	\$	0.37	\$	0.33	\$	0.97	\$	0.90	
NON-GAAP MEASURES-ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE									
Adjusted Net income (1)	\$	138,461	\$	146,597	\$	400,920	\$	411,409	
Adjusted Diluted earnings per share (2)	\$	2.41	\$	2.55	\$	6.96	\$	7.14	

⁽¹⁾ Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items.

Management uses certain non-GAAP measures, such as adjusted net income, adjusted EPS and EBITDA, internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding.

Contact

Lara Mahoney
Vice President, Investor Relations & Corporate Communications
440.204.9985
Lara.Mahoney@nordson.com

⁽²⁾ Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items.